SOURCE: Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

September 03, 2013 09:00 ET

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th

CAMBRIDGE, MA--(Marketwired - Sep 3, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.

Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Follow the official Rodman & Renshaw handle on Twitter @Rodman_2013 and use #Rodman2013 for conference information and updates.

Event: 15th Annual Rodman & Renshaw Global Investment Conference
Date: Tuesday September 10, 2013
Time: 8:45am (Eastern Time)
Location: Room 7.02 (7th floor); Millennium Broadway Hotel in New York City

The presentation will be webcast live. To access the webcast, please visit:
http://wsw.com/webcast/rrshq23/ARTH.

The webcast replay will remain available for 90 days following the live presentation.

About Arch Therapeutics, Inc. (OTCQB: ARTH)
Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's goal is to develop and commercialize products based on our innovative technology platform that make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.

About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD.
Arch Therapeutics, Inc.

Contact Information